Talk:Dopamine reuptake inhibitor
From Wikipedia, the free encyclopedia
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
Wiki Education Foundation-supported course assignment
This article was the subject of a Wiki Education Foundation-supported course assignment, between 3 September 2021 and 16 December 2021. Further details are available on the course page. Student editor(s): Paytonreiner.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 19:44, 16 January 2022 (UTC)
Untitled
Sounds ok.
Daevatgl 20:35, Jun 16, 2004 (UTC)
May 6 2005 edits The Biochemical Basis of Neuropharmacolgy Oxford Press 1996 Chapter 9 Dopamine--McDogm 17:21, 6 May 2005 (UTC)
Should add Adderall in here -- I would but couldnt figure out the proper medical name for it or where it fits in terms of dopamine release.
Binding ligands?
Isn't it the case that most phenethylamine DARIs inhibit by attaching as if they were the regular transporters, and others like the cocaine tropane-types attach or bind as a ligand to the transporter in an entirely different way? It is odd that such a tropane type ligand, if I'm not mistaken, attaches with a higher affinity? 71.34.103.210 (talk) 00:45, 19 April 2009 (UTC)
- ( I'm assuming that by "regular transporters" you meant "regular, to-be-transported substrate" or "endogenous substrate". ) In general, the 2D structure of a drug does not reliably predict its activity ; The fact that some DRIs have a phenethylamine substructure does not mean much.
- The existence of multiple DAT sites and multiple DAT conformations is the subject of on-going research, and AFAIK, it's inconclusive. You can look into :
- PCP site 2, an hypothetical "monoamine transporter negative allosteric modulator site". ( “PCP site 1” would just be a complicated name for NMDAR’s ion channel. )
- Difluoropine, claimed to fold DAT in an inward-facing conformation, meaning it inhibits the reuptake of dopamine but also inhibits its transporter-mediated release.
- Similarly, SoRI-9804 is also claimed to inhibit the reuptake of dopamine while also inhibiting its transporter-mediated release.
- SoRI-20041, claimed to inhibit dopamine reuptake without blocking d-amphetamine mediated release (transport reversal).
- 77.146.231.162 (talk) 17:15, 16 March 2023 (UTC)
Two Errors corrected 9-7-09
I've corrected the following two errors:
- removed benzatropine from the list of DRIs. Benzatropine is an anticholinergic, it has nothing to do with dopamine and dopamine receptors. Its use in Parkison's and other movement disorders has to do with the balance of activity between cholinergic and dopaminergic components of the deep brain movement centers, but it has no effect on dopamine itself.
- added cocaine to the pharmaceutical agents; in the USA it is schedule II, not schedule I, and has important medical uses in ENT/OHNS surgery. —Preceding unsigned comment added by 208.80.67.18 (talk) 17:11, 6 September 2009 (UTC)
- Benzatropine/benztropine is a DRI, hence why I put it on the list: Source. And while cocaine is a pharmaceutical, it's primarily a street drug and its medical use is almost unheard of, so I think the illicit category would be more appropriate. Not to mention its DRI actions aren't actually related to its clinical use either. el3ctr0nika (Talk | Contribs) 09:42, 24 January 2010 (UTC)
Dubious
I tagged the link to physical dependence as dubious. To my knowledge, straight DRIs such as methylphenidate don't cause a lot of "physical dependence". This is partly a language issue: These drugs do cause homeostatic changes in the brain, but philosophy of the mind notwithstanding, I think that that's not usually what is meant by "physical dependence". In my book, "physical dependence" means that there are serious peripheral symptoms upon discontinuation. Suboptimal Username (talk) 17:15, 10 June 2010 (UTC)
There are withdrawal symptoms upon discontinuation, look at cocaine - huge withdrawal symptoms. Even methylphenidate when used at a high enough dose will give withdrawal symptoms --Axxaer (talk) 04:17, 27 September 2010 (UTC)
Cocaine is totally different though, according to the wiki page it is a Serotonin, Norepinephrine and Dopamine reuptake inhibitor. Methylphenidate as well is not selectively a dopamine reuptake inhibitor. I don't really get why you make the link between those two and DRIs Robinsona (talk) 20:47, 11 December 2010 (UTC)
Dopamine reuptake inhibitor that acts just toward the DAT class which dopamine releasing agents can select out of one of either
e.g. dextro- & levo- methamphetamine. Could there be a drug similar to cocaine for instance, that only preforms the function of the former mentioned dextro- (alone) or levo- (alone) by only inhibiting reuptake on those sort of transporters potentially at all? Nagelfar (talk) 05:47, 8 July 2010 (UTC)
- - Levo- and Dextro- are (outdated) terms that refer to a compound's stereochemistry (its enantiomers), not its binding sites.
- - What you’re referring to as a “DAT class“ is likely just NET.
- - Levo-amphetamine and Levo-methamphetamine are selective norepinephrine releasing agents, meaning they have negligible effects (“no effects”) on dopamine transmission at therapeutically relevant doses. The reuptake inhibitor equivalent would therefore be a selective norepinephrine reuptake inhibitor. 77.146.231.162 (talk) 15:24, 16 March 2023 (UTC)
